AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05852795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience
Description: The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios.
Study NCT05618535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler.
Description: Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler.
Study NCT05618535 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Doppler.
Description: Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler.
Study NCT06616207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
Study NCT06616207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution
Description: Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
Study NCT05365659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS03
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Study NCT06171061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic medication
Description: The control group will be given basic medication only. The treatment period is 24 weeks.
Study NCT04206761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
Study NCT04206761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Dual Therapy (ICS/LABA)
Description: High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
Study NCT06616168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)
Description: Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
Study NCT06616168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)
Description: Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
Study NCT04544306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial oral antimicrobial therapy
Description: Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
Study NCT06616168 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Suppositoria for vaginal microflora recovery (Giynoflor)
Description: Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
Study NCT06616168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)
Description: Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
Study NCT06389006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin for Injection
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
Study NCT06389006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
Study NCT06389006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
Study NCT06389006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
Study NCT05027516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocephin
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
Study NCT05513287 — intervention group
Intervention type: OTHER
Intervention: On the period of covid 19
Description: In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
Study NCT05158413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
Study NCT05027516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
Study NCT05158413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose
Description: Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
Study NCT06168240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage. will be applied three days per week for four weeks.
Description: Training will applied 3 days a week, for a total of 4 weeks.
Study NCT06168240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage. will be applied three days per week for four weeks.
Description: Training will applied 3 days a week, for a total of 4 weeks.
Study NCT06250894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1inhibitor
Description: Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
Study NCT04717193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine
Description: Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
Study NCT04717193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine
Description: Infiltration of local anesthetic at incision sites.
Study NCT05973955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia Treatment
Description: The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
Study NCT05973955 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Control
Description: The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
Study NCT06204484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX adjuvant therapy
Description: In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
Study NCT06204484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deferred CAPEOX adjuvant therapy
Description: In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
Study NCT06204484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI intensive adjuvant therapy
Description: In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
Study NCT05401981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story checklist
Description: The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated behavioural assessment
Description: One CRS-R per visit~* 4 SECONDs~* Eye tracking during every clinical assessment~* Recording every 2-4h of the Glasgow Coma Score~* Recording every 2h of the temperature and pupillometer reactivity to light
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated behavioural assessment
Description: One CRS-R per visit~* 4 SECONDs~* Eye tracking during every clinical assessment~* Recording every 2-4h of the Glasgow Coma Score~* Recording every 2h of the temperature and pupillometer reactivity to light
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Act-Pass paradigm
Description: Before and after sedation withdrawal Assessment of infra-clinical response to an active paradigm (attention focalisation or diversion).
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act-Pass paradigm
Description: Before and after sedation withdrawal Assessment of infra-clinical response to an active paradigm (attention focalisation or diversion).
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological measures of circadian and monoamines biomarkers
Description: Systematic urinary sampling every 2 hours for melatonin, cortisol and monoamines metabolites
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biological measures of circadian and monoamines biomarkers
Description: Systematic urinary sampling every 2 hours for melatonin, cortisol and monoamines metabolites
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcriptomic and genomic analysis
Description: Definition of the peripheral cellular clock by 2 transcriptomic measures Constitution of a genomic biobank to analyse the cofounding factors for circadian disruption and differential clinical recovery
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcriptomic and genomic analysis
Description: Definition of the peripheral cellular clock by 2 transcriptomic measures Constitution of a genomic biobank to analyse the cofounding factors for circadian disruption and differential clinical recovery
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography with concomitant environment recording
Description: One 48h polysomnography for the first visit~+ 3\* 24h polysomnography for each visit Synchronised recordings of light, sound, activity in patients' rooms
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polysomnography with concomitant environment recording
Description: One 48h polysomnography for the first visit~+ 3\* 24h polysomnography for each visit Synchronised recordings of light, sound, activity in patients' rooms
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Actimetry
Description: Continuous recording of movements at the wrist during 7 days after sedation withdrawal
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: Continuous recording of movements at the wrist during 7 days after sedation withdrawal
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morphological MRI
Description: Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal
Study NCT04812639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buccal infiltration technique
Description: a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
Study NCT04812639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inferior alveolar nerve block technique
Description: a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morphological MRI
Description: Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.
Description: Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.
Study NCT06245434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.
Description: Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.
Study NCT05779930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 specific Chimeric Antigen Receptor T Cell
Description: Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
Study NCT06243341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lepidium meyenii (MACA)
Description: The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
Study NCT06243341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lepidium meyenii (MACA)
Description: The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
Study NCT06399731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency (10Hz) rTMS
Description: High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
Study NCT06715358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reintervention
Description: * SI! Program environment intervention from 2nd grade through all Elementary Education.~* SI! Program classroom intervention in 2nd grade.~* SI! Program classroom intervention in 5th grade.
Study NCT06715358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late intervention
Description: * SI! Program environment intervention from 5th grade through all Elementary Education.~* SI! Program classroom intervention in 5th grade.
Study NCT06717100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG [Ofev]
Description: Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
Study NCT06399731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
Study NCT06717711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Extracorporeal Shock Wave Therapy (LiESWT)
Description: LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue.
Study NCT06717711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE5 inhibitor (tadalafil)
Description: Phosphodiesterase-5 (PDE5) inhibitors
Study NCT06717711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PDE5 inhibitor (tadalafil)
Description: Phosphodiesterase-5 (PDE5) inhibitors
Study NCT06718751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 650 MG
Description: PO administration of TXA tablet
Study NCT06718751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO administration of placebo tablet
Study NCT06717607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low cylinder toric IOL
Description: Clareon T2 toric IOL implantation
Study NCT06717607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-toric IOL implantation
Description: Clareon non-toric IOL
Study NCT06713031 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cannulated compression screws + iliac bone graft
Description: Using cannulated compression screws + iliac bone graft technique to treat old femoral neck fractures
Study NCT06713031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCS + medial support plate + iliac bone graft
Description: Using DCS + medial support plate + iliac bone graft technique to treat old femoral neck fractures
Study NCT04517435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
Study NCT04517435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.
Study NCT04517435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
Study NCT04517435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
Study NCT04517435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (max 2 mg) IV Vincristine
Study NCT04517435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg PO Prednisone Days 1-5 of 21-day cycle
Study NCT05638906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINT
Description: Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.